Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Wayfair Inc (W)

Wayfair Inc (W)
41.84 x 2 42.20 x 4
Post-market by (Cboe BZX)
41.83 -4.23 (-9.18%) 02/21/25 [NYSE]
41.84 x 2 42.20 x 4
Post-market 42.20 +0.37 (+0.88%) 19:54 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
41.51
Day High
46.80
Open 46.26
Previous Close 46.06 46.06
Volume 5,679,400 5,679,400
Avg Vol 3,783,900 3,783,900
Stochastic %K 28.23% 28.23%
Weighted Alpha -26.87 -26.87
5-Day Change -5.76 (-12.10%) -5.76 (-12.10%)
52-Week Range 37.35 - 76.18 37.35 - 76.18
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,242,094
  • Shares Outstanding, K 125,319
  • Annual Sales, $ 12,003 M
  • Annual Income, $ -738,000 K
  • EBIT $ -516 M
  • EBITDA $ -91 M
  • 60-Month Beta 3.43
  • Price/Sales 0.49
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 61.71% ( +1.18%)
  • Historical Volatility 57.83%
  • IV Percentile 36%
  • IV Rank 26.44%
  • IV High 87.94% on 07/18/24
  • IV Low 52.29% on 06/25/24
  • Put/Call Vol Ratio 1.59
  • Today's Volume 24,928
  • Volume Avg (30-Day) 14,958
  • Put/Call OI Ratio 1.26
  • Today's Open Interest 255,942
  • Open Int (30-Day) 204,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.98
  • Number of Estimates 9
  • High Estimate -0.83
  • Low Estimate -1.16
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +28.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.51 +0.77%
on 02/21/25
Period Open: 48.63
51.16 -18.23%
on 01/31/25
-6.80 (-13.98%)
since 01/21/25
3-Month
41.51 +0.77%
on 02/21/25
Period Open: 42.63
56.55 -26.03%
on 12/13/24
-0.80 (-1.88%)
since 11/21/24
52-Week
37.35 +11.99%
on 11/15/24
Period Open: 48.78
76.18 -45.09%
on 05/13/24
-6.95 (-14.25%)
since 02/21/24

Most Recent Stories

More News
Wayfair's Q4 Earnings Miss Estimates, Revenues Rise Y/Y

Wayfair W reported a fourth-quarter 2024 non-GAAP loss of 25 cents per share, missing the Zacks Consensus Estimate for earnings of 2 cents per share. The company reported a loss of 11 cents per share in...

CARS : 15.89 (-3.76%)
SG : 21.83 (-7.03%)
W : 41.83 (-9.18%)
BBWI : 38.59 (-3.86%)
Wayfair (W) Q4 2024 Earnings Call Transcript

W earnings call for the period ending December 31, 2024.

W : 41.83 (-9.18%)
Wayfair's Mixed Earnings: Revenue Rise

Wayfair reported a revenue beat for the fourth quarter of 2024, but earnings fell short of expectations.

W : 41.83 (-9.18%)
Wayfair’s (NYSE:W) Q4: Beats On Revenue But Stock Drops

Wayfair’s (NYSE:W) Q4: Beats On Revenue But Stock Drops

W : 41.83 (-9.18%)
Wayfair: Q4 Earnings Snapshot

Wayfair: Q4 Earnings Snapshot

W : 41.83 (-9.18%)
Earnings To Watch: Wayfair (W) Reports Q4 Results Tomorrow

Earnings To Watch: Wayfair (W) Reports Q4 Results Tomorrow

W : 41.83 (-9.18%)
AMZN : 216.58 (-2.83%)
COIN : 235.38 (-8.27%)
Q3 Rundown: Wayfair (NYSE:W) Vs Other Online Retail Stocks

Q3 Rundown: Wayfair (NYSE:W) Vs Other Online Retail Stocks

W : 41.83 (-9.18%)
CHWY : 35.12 (-4.90%)
RVLV : 28.61 (-2.45%)
CVNA : 223.30 (-9.86%)
AMZN : 216.58 (-2.83%)
3 Undervalued Stocks You Don’t Want to Overlook

As trade tariffs boost market volatility, investors might want to start considering a few of these discounted stocks that shouldn't be this low.

NVDA : 134.43 (-4.05%)
INTC : 24.87 (-4.68%)
W : 41.83 (-9.18%)
RKT : 13.25 (+4.08%)
TLT : 89.61 (+1.21%)
TSM : 198.24 (-0.93%)
2 Bargain Stocks That Could Soar in 2025

The S&P 500 is up 69% since bottoming in 2022, but the stocks of some industry-leading companies are still trading in the bargain bin.

BABA : 143.75 (+5.72%)
W : 41.83 (-9.18%)
Why Wayfair, Dollar General, and Five Below Stocks All Popped Today

Stocks soared in the first trading day of President Trump's second term, and some of the biggest winners today were Wayfair (NYSE: W), Dollar General (NYSE: DG) , and Five Below (NASDAQ: FIVE) .

FIVE : 85.92 (-3.63%)
DG : 76.69 (+0.74%)
W : 41.83 (-9.18%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Wayfair Inc. is one of the world's leading online sellers of home goods products, consisting of furniture and home decor. It operates worldwide through Wayfair.com and four other branded websites: Joss & Main, AllModern, Birch Lane and Perigold. The company operates in Canada, the U.K. and Germany through...

See More

Key Turning Points

3rd Resistance Point 50.54
2nd Resistance Point 48.67
1st Resistance Point 45.25
Last Price 41.83
1st Support Level 39.96
2nd Support Level 38.09
3rd Support Level 34.67

See More

52-Week High 76.18
Fibonacci 61.8% 61.34
Fibonacci 50% 56.76
Fibonacci 38.2% 52.18
Last Price 41.83
52-Week Low 37.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements